BACKGROUND:Retinoids have shown antiproliferative and chemopreventive activity. We analyzed data from a randomized, placebo-controlled chemoprevention trial to determine whether a 3-month treatment with either 9-cis-retinoic acid (RA) or 13-cis-RA and alpha-tocopherol reduced Ki-67, a proliferation biomarker, in the bronchial epithelium. METHODS:Former smokers (n = 225) were randomly assigned to receive 3 months of daily oral 9-cis-RA (100 mg), 13-cis-RA (1 mg/kg) and alpha-tocopherol (1200 IU), or placebo. Bronchoscopic biopsy specimens obtained before and after treatment were immunohistochemically assessed for changes in the Ki-67 proliferative index (i.e., percentage of cells with Ki-67-positive nuclear staining) in the basal and parabasal layers of the bronchial epithelium. Per-subject and per-biopsy site analyses were conducted. Multicovariable analyses, including a mixed-effects model and a generalized estimating equations model, were used to investigate the treatment effect (Ki-67 labeling index and percentage of bronchial epithelial biopsy sites with a Ki-67 index > or = 5%) with adjustment for multiple covariates, such as smoking history and metaplasia. Coefficient estimates and 95% confidence intervals (CIs) were obtained from the models. All statistical tests were two-sided. RESULTS: In per-subject analyses, Ki-67 labeling in the basal layer was not changed by any treatment; the percentage of subjects with a high Ki-67 labeling in the parabasal layer dropped statistically significantly after treatment with 13-cis-RA and alpha-tocopherol treatment (P = .04) compared with placebo, but the drop was not statistically significant after 9-cis-RA treatment (P = .17). A similar effect was observed in the parabasal layer in a per-site analysis; the percentage of sites with high Ki-67 labeling dropped statistically significantly after 9-cis-RA treatment (coefficient estimate = -0.72, 95% CI = -1.24 to -0.20; P = .007) compared with placebo, and after 13-cis-RA and alpha-tocopherol treatment (coefficient estimate = -0.66, 95% CI = -1.15 to -0.17; P = .008). CONCLUSIONS: In per-subject analyses, treatment with 13-cis-RA and alpha-tocopherol, compared with placebo, was statistically significantly associated with reduced bronchial epithelial cell proliferation; treatment with 9-cis-RA was not. In per-site analyses, statistically significant associations were obtained with both treatments.
RCT Entities:
BACKGROUND:Retinoids have shown antiproliferative and chemopreventive activity. We analyzed data from a randomized, placebo-controlled chemoprevention trial to determine whether a 3-month treatment with either 9-cis-retinoic acid (RA) or 13-cis-RA and alpha-tocopherol reduced Ki-67, a proliferation biomarker, in the bronchial epithelium. METHODS: Former smokers (n = 225) were randomly assigned to receive 3 months of daily oral 9-cis-RA (100 mg), 13-cis-RA (1 mg/kg) and alpha-tocopherol (1200 IU), or placebo. Bronchoscopic biopsy specimens obtained before and after treatment were immunohistochemically assessed for changes in the Ki-67 proliferative index (i.e., percentage of cells with Ki-67-positive nuclear staining) in the basal and parabasal layers of the bronchial epithelium. Per-subject and per-biopsy site analyses were conducted. Multicovariable analyses, including a mixed-effects model and a generalized estimating equations model, were used to investigate the treatment effect (Ki-67 labeling index and percentage of bronchial epithelial biopsy sites with a Ki-67 index > or = 5%) with adjustment for multiple covariates, such as smoking history and metaplasia. Coefficient estimates and 95% confidence intervals (CIs) were obtained from the models. All statistical tests were two-sided. RESULTS: In per-subject analyses, Ki-67 labeling in the basal layer was not changed by any treatment; the percentage of subjects with a high Ki-67 labeling in the parabasal layer dropped statistically significantly after treatment with 13-cis-RA and alpha-tocopherol treatment (P = .04) compared with placebo, but the drop was not statistically significant after 9-cis-RA treatment (P = .17). A similar effect was observed in the parabasal layer in a per-site analysis; the percentage of sites with high Ki-67 labeling dropped statistically significantly after 9-cis-RA treatment (coefficient estimate = -0.72, 95% CI = -1.24 to -0.20; P = .007) compared with placebo, and after 13-cis-RA and alpha-tocopherol treatment (coefficient estimate = -0.66, 95% CI = -1.15 to -0.17; P = .008). CONCLUSIONS: In per-subject analyses, treatment with 13-cis-RA and alpha-tocopherol, compared with placebo, was statistically significantly associated with reduced bronchial epithelial cell proliferation; treatment with 9-cis-RA was not. In per-site analyses, statistically significant associations were obtained with both treatments.
Authors: Jenny T Mao; Michael C Fishbein; Bradley Adams; Michael D Roth; Lee Goodglick; Longsheng Hong; Marie Burdick; E Robert M Strieter; Carmack Holmes; Donald P Tashkin; Steven M Dubinett Journal: Clin Cancer Res Date: 2006-01-01 Impact factor: 12.531
Authors: Gary J Kelloff; Scott M Lippman; Andrew J Dannenberg; Caroline C Sigman; Homer L Pearce; Brian J Reid; Eva Szabo; V Craig Jordan; Margaret R Spitz; Gordon B Mills; Vali A Papadimitrakopoulou; Reuben Lotan; Bharat B Aggarwal; Robert S Bresalier; Jeri Kim; Banu Arun; Karen H Lu; Melanie E Thomas; Helen E Rhodes; Molly A Brewer; Michele Follen; Dong M Shin; Howard L Parnes; Jill M Siegfried; Alison A Evans; William J Blot; Wong-Ho Chow; Patricia L Blount; Carlo C Maley; Kenneth K Wang; Stephen Lam; J Jack Lee; Steven M Dubinett; Paul F Engstrom; Frank L Meyskens; Joyce O'Shaughnessy; Ernest T Hawk; Bernard Levin; William G Nelson; Waun Ki Hong Journal: Clin Cancer Res Date: 2006-06-15 Impact factor: 12.531
Authors: Daniel T Merrick; John Kittelson; Ralph Winterhalder; Georgia Kotantoulas; Steen Ingeberg; Robert L Keith; Timothy C Kennedy; York E Miller; Wilbur A Franklin; Fred R Hirsch Journal: Clin Cancer Res Date: 2006-04-01 Impact factor: 12.531
Authors: Timothy C Kennedy; Wilbur A Franklin; Sheila A Prindiville; Robert Cook; Edward C Dempsey; Robert L Keith; Fred R Hirsch; Thomas A Merrick; Kenneth R Shroyer; Thomas L Petty; Tim Byers; Paul A Bunn; York E Miller Journal: Lung Cancer Date: 2005-04-14 Impact factor: 5.705
Authors: Jun Yang; Nithya Ramnath; Kirsten B Moysich; Harold L Asch; Helen Swede; Sadir J Alrawi; Joel Huberman; Joseph Geradts; John S J Brooks; Dongfeng Tan Journal: BMC Cancer Date: 2006-08-01 Impact factor: 4.430
Authors: Robert L Keith; Patrick J Blatchford; John Kittelson; John D Minna; Karen Kelly; Pierre P Massion; Wilbur A Franklin; Jenny Mao; David O Wilson; Daniel T Merrick; Fred R Hirsch; Timothy C Kennedy; Paul A Bunn; Mark W Geraci; York E Miller Journal: Cancer Prev Res (Phila) Date: 2011-06
Authors: Karen Kelly; John Kittelson; Wilbur A Franklin; Timothy C Kennedy; Catherine E Klein; Robert L Keith; Edward C Dempsey; Marina Lewis; Mary K Jackson; Fred R Hirsch; Paul A Bunn; York E Miller Journal: Cancer Prev Res (Phila) Date: 2009-04-28
Authors: Hyunseok Kang; Theresa W Gillespie; Michael Goodman; Seth A Brodie; Mina Brandes; Maria Ribeiro; Suresh S Ramalingam; Dong M Shin; Fadlo R Khuri; Johann Christoph Brandes Journal: Cancer Date: 2014-03-24 Impact factor: 6.860
Authors: Edward S Kim; Waun K Hong; J Jack Lee; Li Mao; Rodolfo C Morice; Diane D Liu; Carlos A Jimenez; Georgie A Eapen; Reuben Lotan; Ximing Tang; Robert A Newman; Ignacio I Wistuba; Jonathan M Kurie Journal: Cancer Prev Res (Phila) Date: 2010-01-26
Authors: Mridul Datta; Edward G Shaw; Glenn J Lesser; L Douglas Case; Mara Z Vitolins; Charles Schneider; Bart Frizzell; Christopher Sullivan; Mark Lively; Elizabeth Franzmann; Jennifer J Hu Journal: Integr Cancer Ther Date: 2017-01-19 Impact factor: 3.279